基于药物基因组学的药物流行病学研究设计概述  

Overview of Pharmacoepidemiological Research Design Based on Pharmacogenomics

作　　者：张伟霞[1] Zhang Weixia(Department of Pharmacy,Ruijin Hospital,Shanghai Jiaotong University School of Medicine,Shanghai 200025,China)

机构地区：[1]上海交通大学医学院附属瑞金医院药剂科,上海200025

出　　处：《药物流行病学杂志》2021年第12期787-792,共6页Chinese Journal of Pharmacoepidemiology

基　　金：上海市“医苑新星”青年医学人才培养资助计划-临床药师项目。

摘　　要：药物基因组学在新药临床试验及个体化用药中发挥着重要作用。基因组水平的生物标志物可用在药物流行病学研究的设计中,用于识别个体对药物疗效有差异的原因,以及有药物毒性风险的个体。本文介绍了药物基因组学生物标志物的筛选方法,以及举例介绍了如何用药物流行病学的方法开展药物基因组学研究,包括临床随机对照试验和观察性研究。Pharmacogenomics plays an important role in clinical trials of new drugs and individualized medication. Genomic level biomarkers can be used in the design of pharmacoepidemiology studies to identify the reasons for differences in the efficacy of drugs between individuals and individuals who are at risk of drug toxicity. This paper introduces the screening methods of pharmacogenomics biomarkers, and illustrate how to carry out pharmacogenomic research by means of pharmacoepidemiology methods, including randomized controlled trial(RCT) and observational studies.

关 键 词：药物基因组学 药物流行病学 随机对照试验 观察性研究 生物标志物 

分 类 号：R181.35[医药卫生—流行病学] R968[医药卫生—公共卫生与预防医学]